Adaptive Biotechnologies Signs Deal with Pfizer Worth Up to $890M for Rheumatoid Arthritis Research

Adaptive Biotechnologies announced two non-exclusive licensing agreements with Pfizer. The deals include a target discovery collaboration to identify disease-driving T-cell receptors in rheumatoid arthritis and a data licensing agreement granting Pfizer access to Adaptive’s proprietary TCR-antigen datasets. The agreements support AI-enabled drug discovery, with Adaptive eligible for upfront payments and significant potential milestones.